



Published in final edited form as:

Magn Reson Med. 2016 May ; 75(5): 2107–2111. doi:10.1002/mrm.26151.

Safety and Technique of Ferumoxytol Administration for MRI

Shreyas S. Vasanawala^{1,*}, Kim-Lien Nguyen², Michael D. Hope³, Mellena D. Bridges⁴, Thomas A. Hope³, Scott B. Reeder⁵, and Mustafa R. Bashir⁶

¹Department of Radiology, Stanford University, Stanford, CA

²Department of Medicine, David Geffen School of Medicine at UCLA, University of California, Los Angeles

³Department of Radiology, University of California, San Francisco

⁴Department of Radiology, Mayo Clinic Florida, Jacksonville, FL

⁵Departments of Radiology, Medical Physics, Biomedical Engineering, and Emergency Medicine, University of Wisconsin, Madison, WI

⁶Center for Advanced Magnetic Resonance Development and Department of Radiology, Duke University, Durham, NC

Abstract

Ferumoxytol is an ultrasmall superparamagnetic iron oxide agent marketed for the treatment of anemia. There has been increasing interest in its properties as an MRI contrast agent as well as greater awareness of its adverse event profile. This mini-review summarizes the current state of knowledge of the risks of ferumoxytol and methods of administration.

Keywords

ferumoxytol; iron oxide; safety; contrast agent

OVERVIEW

In recent years, ferumoxytol, an intravenously (IV) administered ultrasmall superparamagnetic iron oxide agent marketed for treatment of anemia in adult patients, has attracted interest from the imaging community for a variety of clinical and research applications. Because of T₁ shortening effects, long blood-pool residence time, and clearance through the reticuloendothelial system, ferumoxytol has been recently adopted for off-label clinical use as a vascular and nodal metastasis contrast agent, and as a research tool for studies involving macrophages and cell labeling. Furthermore, because ferumoxytol does not contain gadolinium, it may be an attractive alternative in those patients with renal failure who may be at risk of gadolinium-associated nephrogenic systemic fibrosis (NSF). Although

*Correspondence to: Shreyas S. Vasanawala, Dept. of Radiology, Stanford University, 725 Welch Road, Stanford, CA 94305. vasanawala@stanford.edu.

ferumoxytol has a favorable premarketing safety profile, on March 30, 2015, the FDA strengthened its existing warning about the adverse event profile of ferumoxytol.

Associated Adverse Events and Relative Risk

Adverse Events in Postmarketing Clinical Trials—To date, postmarketing safety data are only available for therapeutic use of ferumoxytol. These include three multinational, randomized clinical trials (1–3) (n = 1094) and two nonrandomized studies (4,5) (n = 8726). Most reported adverse events were mild, transient, and typically associated with the infusion process, although mild arthralgia/myalgia and headaches occurred up to 48h postinfusion in one study (5). One study included 15 subjects with multiple drug allergies or asthma: These subjects received 125 mg methylprednisolone prophylactically. Aggregate adverse events are reported in Table 1A.

Serious adverse events included hypersensitivity (2,4) and hypotension (4). The reported rates of anaphylaxis ranged from 0.02% with 2/8666 (4) to 1.3% with 1/80 (3), with a pooled aggregate rate of 0.03% (3/10425) based on published studies(1–4). Reported deaths (n = 3) were considered unrelated to ferumoxytol (1,2). The incidence of composite cardiovascular adverse event endpoint (CCAEE), which aggregates the incidence of a variety of cardiovascular adverse events including nonfatal myocardial infarction, heart failure, moderate-to-severe hypertension, and hospitalization resulting from any cardiovascular cause, was 2.7% (1).

Postmarket Surveillance—Since 2009, approximately 1.2 million therapeutic doses of ferumoxytol have been administered. In March 2015, the US Food & Drug Administration (FDA) Adverse Event Reporting System showed 79 anaphylactic reactions, with 18 fatalities despite immediate intervention. These deaths resulted in a boxed warning in March 2015 (<http://www.fda.gov/Drugs/DrugSafety/ucm440138.htm>). Twenty-four percent of these patients had multiple drug allergies, and nearly half of these anaphylactic reactions occurred within 5 min of administration. This rate of adverse events is lower than the rates initially reported in Phase II–III clinical trials.

Off-Label Imaging Use—To date, approximately 2000 patients across our institutions have received ferumoxytol for clinical MR imaging with standard monitoring procedures. We have had one case of an anaphylactoid reaction in a patient with multiple previous allergies who experienced diffuse cutaneous erythema (skin reddening) within seconds of starting a slow ferumoxytol infusion, followed by hypotension and delayed capillary refill. The infusion was stopped and the patient received IV fluids, IV diphenhydramine, IV ranitidine, and intramuscular epinephrine, resulting in resolution of erythema and hypotension. The MR scan was completed without further event. A literature search for ferumoxytol use in MRI performed in July 2015 revealed one report of a grade 2 allergic reaction (6). The reported patient had hives and throat swelling, associated with an infusion dose of 2.5 mg Fe/kg, which resolved with IV diphenhydramine. The imaging studies reviewed did not systematically evaluate for safety events.

Mechanism—IV iron administration, in general, can be associated with anaphylaxis and hypotension; ferumoxytol was specifically designed to minimize these risks. In Phase I–III studies, ferumoxytol demonstrated low immunogenicity (7,8) and generated the lowest amount of labile-free iron compared with other IV iron therapies (9–11). Furthermore, ferumoxytol’s isotonic formulation may partly explain the absence of adverse events related to rapid injection, unlike other iron preparations. Acute effects have been attributed to a combination of bioactive-free iron and mast cell release (12). Reaction recurrence can be mitigated by premedication with methylprednisolone, whereas nonsteroidal anti-inflammatory drugs can be used to prevent delayed arthralgias (12). Because diphenhydramine can cause somnolence, diaphoresis, hypotension, and tachycardia, premedication with diphenhydramine may actually worsen the acute response (13).

Risk Relative to Iodine- and Gadolinium-Based Contrast Agents—Risks of serious adverse events with ferumoxytol based on postmarket surveillance are similar to those associated with ionic iodinated contrast agents, and higher than those with gadolinium-based agents or nonionic iodinated contrast material (14,15). However, the risks associated with iodinated and gadolinium-based agents in patients with severe renal disease (iodinated contrast-induced nephrotoxicity and NSF) are even higher and can be fatal (16,17). Gadolinium deposits in deep nuclei of the brain (18) and delayed cases of NSF have been reported up to a decade after exposure (19), although the clinical significance of gadolinium deposition in the brain is unknown at this time.

Administration Practices

Work to date has largely been focused at single institutions, with fairly limited interaction among imaging centers. Administration details are inconsistently reported in the imaging literature. Based on the experience of the authors of this review, typical ferumoxytol doses for imaging range from 1 to 7.5 mg/kg, with most cases between 2 and 4 mg/kg. In most cases, a significantly smaller dose is given compared with the standard full therapeutic dose of 1020 mg (which is two doses of 510 mg and equates to 14.6 mg/kg for a 70-kg adult) for treatment of anemia, and reported doses are clustered around the 4 mg/kg recommendation produced by the seminal preclinical study by Prince et al (20). All reporting groups dilute the administered dose to a total volume of 24–60 mL for adults using saline. Injection rates at least partly reflect specific imaging indications, and range from a slow infusion (for lymph node and steady-state imaging) to bolus injections of 0.1–0.2 mg/(kg/s) for some angiographic applications (6,21,22). Higher injection rates and concentrations may be limited by artifacts from R2* effects (23,24). Additionally, the FDA explicitly recommends a slow infusion of a diluted agent (Table 1B); therefore, a careful assessment of specific benefits and risks of bolus administration should be undertaken. Of note, MR image contrast may be altered by ferumoxytol for days to months after administration, whether for therapeutic or diagnostic purposes.

Evaluation for preexisting iron overload, absent in the imaging literature, is undertaken only by a minority of our groups, either through liver R2* measurements or serum ferritin levels. Most, though not all, reporting participants monitor patients for reactions for at least 30 min postadministration, including heart rate, blood pressure, and oxygen saturation.

Administration is typically in a hospital setting, in which equipment and trained personnel for managing contrast reactions are readily available.

Ferumoxytol is distributed in a single-use vial containing 510 mg of iron. For multiple uses, the agent should be withdrawn and diluted in a sterile hood by trained pharmacy personnel. Typically, once a vial is opened, because of concerns about sterility, the final dose should be administered within 4 h after opening the vial. Although costs vary by region, ferumoxytol is generally more expensive than gadolinium agents; thus, the challenge of properly obtaining multiple uses from a single vial may be worth addressing in consultation with the institutional clinical pharmacy. However, in certain populations such as those with severely impaired renal function, in which no other options exist, the value of the diagnostic information obtained would outweigh the cost factor.

Similar to imaging procedures that involve ionizing radiation and off-label use of iodinated or gadolinium-based contrast agents, some of our clinical practices do not obtain informed consent for ferumoxytol administration (25,26). As has been reviewed in this article, the primary risk is anaphylaxis, which is a rare occurrence. Currently, for clinical off-label use of iodinated and gadolinium-based contrast agents, there is no consensus as to whether consent should be obtained.

Potential Clinical Uses

Vascular Imaging—Ferumoxytol has been used in magnetic resonance angiography (MRA) of abdominal aortic aneurysms, evaluation for endoleaks after stentgraft repair of aneurysms, and assessment for renal artery stenosis (27–30). Given the known risks of gadolinium-based agents in patients with significant renal impairment, ferumoxytol has also been reported for renal transplant MRA (31,32). Noncontrast MRA and venography techniques should be considered as alternatives in these settings, balancing the speed, resolution, and reliability of the various approaches. Additionally, several groups have described the use of ferumoxytol for the imaging of deep vein thrombosis and pulmonary thromboembolism (33–36), as well as pediatric cardiovascular imaging (37,38). Quantitative first-pass perfusion MRI has also been described (39,40), along with blood signal suppression for lymphangiography (41).

Macrophage Imaging—Macrophage uptake of ferumoxytol allows the assessment of macrophage migration and localization. Thus, the immune response to brain tumors, such as gliomas and lymphomas, may enable the imaging of tumor extent (22,42). Similarly, ferumoxytol uptake has been associated with instability and impending rupture of vascular lesions, including intracranial aneurysms, arteriovenous malformations, and carotid plaques, based on macrophage localization (43–47). Finally, lymph nodes replaced by metastatic tumor will show reduced or absent uptake, although this is better established for other iron-based agents (48–51).

SUMMARY AND RECOMMENDATIONS

Ferumoxytol, although approved as a therapeutic agent, may be useful as an MRI contrast agent. Potential users should consider guidance from their institution's pharmacy committee

before off-label clinical use. For research, investigators should seek the guidance of their local ethics board or institutional review board, and perform research studies only under approved protocols. Although the risk of acute adverse events with ferumoxytol is likely higher than that of gadolinium-based agents, ferumoxytol has a strong safety profile and may provide unique diagnostic information. Furthermore, it may be a valuable alternative for patients with renal insufficiency who may be at risk for NSF should they receive a gadolinium-based contrast agent. Ferumoxytol, like iodinated and gadolinium-based contrast agents, should be administered in an environment in which trained personnel, monitoring equipment, and resuscitation supplies are immediately available. Just as with other contrast agents, additional caution should be exercised in patients with prior or multiple drug allergies.

References

1. Hetzel D, Strauss W, Bernard K, Li Z, Urboniene A, Allen LF. A Phase III, randomized, open-label trial of ferumoxytol compared with iron sucrose for the treatment of iron deficiency anemia in patients with a history of unsatisfactory oral iron therapy. *Am J Hematol.* 2014; 89:646–650. [PubMed: 24639149]
2. Vadhan-Raj S, Strauss W, Ford D, Bernard K, Boccia R, Li J, Allen LF. Efficacy and safety of IV ferumoxytol for adults with iron deficiency anemia previously unresponsive to or unable to tolerate oral iron. *Am J Hematol.* 2014; 89:7–12. [PubMed: 23983177]
3. Macdougall IC, Strauss WE, McLaughlin J, Li Z, Dellanna F, Hertel J. A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD. *Clin J Am Soc Nephrol.* 2014; 9:705–712. [PubMed: 24458078]
4. Schiller B, Bhat P, Sharma A. Safety and effectiveness of ferumoxytol in hemodialysis patients at 3 dialysis chains in the United States over a 12-month period. *Clin Ther.* 2014; 36:70–83. [PubMed: 24315802]
5. Auerbach M, Strauss W, Auerbach S, Rineer S, Bahrain H. Safety and efficacy of total dose infusion of 1,020 mg of ferumoxytol administered over 15 min. *Am J Hematol.* 2013; 88:944–947. [PubMed: 23828252]
6. Turkbey B, Agarwal HK, Shih J, et al. A phase I dosing study of ferumoxytol for MR lymphography at 3 T in patients with prostate cancer. *AJR Am J Roentgenol.* 2015; 205:64–69. [PubMed: 26102381]
7. Pai AB, Garba AO. Ferumoxytol: a silver lining in the treatment of anemia of chronic kidney disease or another dark cloud? *J Blood Med.* 2012; 3:77–85. [PubMed: 22973119]
8. Provenzano R, Schiller B, Rao M, Coyne D, Brenner L, Pereira BJG. Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients. *Clin J Am Soc Nephrol.* 2009; 4:386–393. [PubMed: 19176796]
9. Jahn MR, Andreassen HB, Futterer S, et al. A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications. *Eur J Pharm Biopharm.* 2011; 78:480–491. [PubMed: 21439379]
10. Balakrishnan VS, Rao M, Kausz AT, Brenner L, Pereira BJG, Frigo TB, Lewis JM. Physicochemical properties of ferumoxytol, a new intravenous iron preparation. *Eur J Clin Invest.* 2009; 39:489–496. [PubMed: 19397688]
11. Neiser S, Rentsch D, Dippon U, et al. Physico-chemical properties of the new generation IV iron preparations ferumoxytol, iron isomaltoside 1000 and ferric carboxymaltose. *Biometals.* 2015; 28:615–635. [PubMed: 25801756]
12. Bircher AJ, Auerbach M. Hypersensitivity from intravenous iron products. *Immunol Allergy Clin North Am.* 2014; 34:707–723. x–xi. [PubMed: 25017687]
13. Barton JC, Barton EH, Bertoli LF, Gothard CH, Sherrer JS. Intravenous iron dextran therapy in patients with iron deficiency and normal renal function who failed to respond to or did not tolerate oral iron supplementation. *Am J Med.* 2000; 109:27–32. [PubMed: 10936475]

14. Katayama H, Yamaguchi K, Kozuka T, Takashima T, Seez P, Matsuura K. Adverse reactions to ionic and nonionic contrast media. A report from the Japanese Committee on the Safety of Contrast Media. *Radiology*. 1990; 175:621–628. [PubMed: 2343107]
15. Prince MR, Zhang H, Zou Z, Staron RB, Brill PW. Incidence of immediate gadolinium contrast media reactions. *AJR Am J Roentgenol* [Internet]. 2011; 196:W138–W143.
16. Braverman IM, Cowper S. Nephrogenic systemic fibrosis. *F1000 Med Rep*. 2010; 2:84. [PubMed: 21283650]
17. Zou Z, Ma L. Nephrogenic systemic fibrosis: review of 408 biopsy-confirmed cases. *Indian J Dermatol*. 2011; 56:65–73. [PubMed: 21572796]
18. McDonald RJ, McDonald JS, Kallmes DF, Jentoft ME, Murray DL, Thielen KR, Williamson EE, Eckel LJ. Intracranial gadolinium deposition after contrast-enhanced MR imaging. *Radiology*. 2015; 275:772–782. [PubMed: 25742194]
19. Larson KN, Gagnon AL, Darling MD, Patterson JW, Cropley TG. Nephrogenic systemic fibrosis manifesting a decade after exposure to gadolinium. *JAMA Dermatol*. 2015; 151:1117–1120. [10.1001/jamadermatol.2015.0976](https://doi.org/10.1001/jamadermatol.2015.0976) [PubMed: 26017458]
20. Prince MR, Zhang HL, Chabra SG, Jacobs P, Wang Y. A pilot investigation of new superparamagnetic iron oxide (ferumoxytol) as a contrast agent for cardiovascular MRI. *J Xray Sci Technol*. 2003; 11:231–240. [PubMed: 22388293]
21. Li W, Tutton S, Vu AT, Pierchala L, Li BSY, Lewis JM, Prasad PV, Edelman RR. First-pass contrast-enhanced magnetic resonance angiography in humans using ferumoxytol, a novel ultrasmall superparamagnetic iron oxide (USPIO)-based blood pool agent. *J Magn Reson Imaging*. 2005; 21:46–52. [PubMed: 15611942]
22. Hamilton BE, Nesbit GM, Dósa E, Gahramanov S, Rooney B, Nesbit EG, Raines J, Neuwelt EA. Comparative analysis of ferumoxytol and gadoteridol enhancement using T1- and T2-weighted MRI in neuroimaging. *AJR Am J Roentgenol*. 2011; 197:981–988. [PubMed: 21940589]
23. Fananapazir G, Marin D, Suhocki PV, Kim CY, Bashir MR. Vascular artifact mimicking thrombosis on MR imaging using ferumoxytol as a contrast agent in abdominal vascular assessment. *J Vasc Interv Radiol*. 2014; 25:969–976. [PubMed: 24630749]
24. Reeder SB, Smith MR, Hernando D. Mathematical optimization of contrast concentration for t1-weighted spoiled gradient echo imaging. *Magn Reson Med*. 2015
25. Harvey HB, Brink JA, Frush DP. Informed consent for radiation risk from CT is unjustified based on the current scientific evidence. *Radiology*. 2015; 275:321–325. [PubMed: 25906299]
26. Nieuvelstein RAJ, Frush DP. Should we obtain informed consent for examinations that expose patients to radiation? *AJR Am J Roentgenol*. 2012; 199:664–669. [PubMed: 22915409]
27. Bremerich J, Bilecen D, Reimer P. MR angiography with blood pool contrast agents. *Eur Radiol*. 2007; 17:3017–3024. [PubMed: 17639407]
28. Stabi KL, Bendz LM. Ferumoxytol use as an intravenous contrast agent for magnetic resonance angiography. *Ann Pharmacother*. 2011; 45:1571–1575. [PubMed: 22045905]
29. Ersoy H, Jacobs P, Kent CK, Prince MR. Blood pool MR angiography of aortic stent-graft endoleak. *AJR Am J Roentgenol*. 2004; 182:1181–1186. [PubMed: 15100115]
30. Bashir MR, Bhatti L, Marin D, Nelson RC. Emerging applications for ferumoxytol as a contrast agent in MRI. *J Magn Reson Imaging*. 2014; 41(4):884–898. [PubMed: 24974785]
31. Bashir MR, Jaffe TA, Brennan TV, Patel UD, Ellis MJ. Renal transplant imaging using magnetic resonance angiography with a non-nephrotoxic contrast agent. *Transplantation*. 2013; 96:91–96. [PubMed: 23680931]
32. Sofue K, Vikraman DS, Jaffe TA, Chaubal GN, Bashir MR. Graft kidney torsion after simultaneous kidney-pancreas transplant: Report of 2 cases and literature review. *J Comput Assist Tomogr*. 2015; 39:506–509. Review. [10.1097/RCT.0000000000000250](https://doi.org/10.1097/RCT.0000000000000250) [PubMed: 25853775]
33. Enden T, Storås TH, Negård A, Haig Y, Sandvik L, Gjesdal K-I, Sandset PM, Kløw N-E. Visualization of deep veins and detection of deep vein thrombosis (DVT) with balanced turbo field echo (b-TFE) and contrast-enhanced T1 fast field echo (CE-FFE) using a blood pool agent (BPA). *J Magn Reson Imaging*. 2010; 31:416–424. [PubMed: 20099355]
34. Hadzadeh DR, Kukuk GM, Fahlenkamp UL, Pressacco J, Schafer C, Rabe E, Koscielny A, Verrel F, Schild HH, Willinek WA. Simultaneous MR arteriography and venography with blood pool

- contrast agent detects deep venous thrombosis in suspected arterial disease. *AJR Am J Roentgenol.* 2012; 198:1188–1195. [PubMed: 22528912]
35. Li W, Salantri J, Tutton S, Dunkle EE, Schneider JR, Caprini JA, Pierchala LN, Jacobs PM, Edelman RR. Lower extremity deep venous thrombosis: evaluation with ferumoxytol-enhanced MR imaging and dual-contrast mechanism—preliminary experience 1. *Radiology.* 2007; 242:873–881. [PubMed: 17325072]
 36. Bashir MR, Mody R, Neville A, Javan R, Seaman D, Kim CY, Gupta RT, Jaffe TA. Retrospective assessment of the utility of an iron-based agent for contrast-enhanced magnetic resonance venography in patients with endstage renal diseases. *J Magn Reson Imaging.* 2014; 40:113–118. [PubMed: 24130008]
 37. Nayak AB, Luhar A, Hanudel M, Gales B, Hall TR, Finn JP, Salusky IB, Zaritsky J. High-resolution, whole-body vascular imaging with ferumoxytol as an alternative to gadolinium agents in a pediatric chronic kidney disease cohort. *Pediatr Nephrol.* 2015; 30:515–521. [PubMed: 25212105]
 38. Ruangwattanapaisarn N, Hsiao A, Vasanawala SS. Ferumoxytol as an off-label contrast agent in body 3T MR angiography: a pilot study in children. *Pediatr Radiol.* 2015; 45:831–839. [PubMed: 25427433]
 39. Gahramanov S, Muldoon LL, Varallyay CG, Li X, Kraemer DF, Fu R, Hamilton BE, Rooney WD, Neuwelt EA. Pseudoprogression of glioblastoma after chemo- and radiation therapy: diagnosis by using dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging with ferumoxytol versus gadoteridol and correlation with survival. *Radiology.* 2013; 266:842–852. [PubMed: 23204544]
 40. Thompson EM, Guillaume DJ, Dósa E, Li X, Nazemi KJ, Gahramanov S, Hamilton BE, Neuwelt EA. Dual contrast perfusion MRI in a single imaging session for assessment of pediatric brain tumors. *J Neurooncol.* 2012; 109:105–114. [PubMed: 22528798]
 41. Maki JH, Neligan PC, Briller N, Mitsumori LM, Wilson GJ. Dark blood magnetic resonance lymphangiography using dual-agent relaxivity contrast (DARC-MRL): a novel method combining gadolinium and iron contrast agents. *Curr Probl Diagn Radiol.* 2015 pii: S0363-0188(15)00122-X. Epub ahead of print. 10.1067/j.cpradiol.2015.08.003
 42. Farrell BT, Hamilton BE, Dósa E, et al. Using iron oxide nanoparticles to diagnose CNS inflammatory diseases and PCNSL. *Neurology.* 2013; 81:256–263. [PubMed: 23771486]
 43. Chen Y, Pawlikowska L, Yao JS, Shen F, Zhai W, Achrol AS, Lawton MT, Kwok P-Y, Yang G-Y, Young WL. Interleukin-6 involvement in brain arteriovenous malformations. *Ann Neurol.* 2006; 59:72–80. [PubMed: 16278864]
 44. Chen Y, Zhu W, Bollen AW, Lawton MT, Barbaro NM, Dowd CF, Hashimoto T, Yang G-Y, Young WL. Evidence of inflammatory cell involvement in brain arteriovenous malformations. *Neurosurgery.* 2008; 62:1340–1350. [PubMed: 18825001]
 45. Hasan DM, Chalouhi N, Jabbour P, Magnotta VA, Kung DK, Young WL. Imaging aspirin effect on macrophages in the wall of human cerebral aneurysms using ferumoxytol-enhanced MRI: preliminary results. *J Neuroradiol.* 2013; 40:187–191. [PubMed: 23428244]
 46. Hasan D, Chalouhi N, Jabbour P, Dumont AS, Kung DK, Magnotta VA, Young WL, Hashimoto T, Winn HR, Heistad D. Early change in ferumoxytol-enhanced magnetic resonance imaging signal suggests unstable human cerebral aneurysm: a pilot study. *Stroke.* 2012; 43:3258–3265. [PubMed: 23138441]
 47. Herborn CU, Vogt FM, Lauenstein TC, Dirsch O, Corot C, Robert P, Ruehm SG. Magnetic resonance imaging of experimental atherosclerotic plaque: comparison of two ultrasmall superparamagnetic particles of iron oxide. *J Magn Reson Imaging.* 2006; 24:388–393. [PubMed: 16791857]
 48. Anzai Y, Piccoli CW, Outwater EK, et al. Evaluation of neck and body metastases to nodes with ferumoxtran 10-enhanced MR imaging: phase III safety and efficacy study. *Radiology.* 2003; 228:777–788. [PubMed: 12954896]
 49. Heesakkers RAM, Jager GJ, Hovels AM, de Hoop B, van den Bosch HCM, Raat F, Witjes JA, Mulders PFA, van der Kaa CH, Barentsz JO. Prostate cancer: detection of lymph node metastases outside the routine surgical area with ferumoxtran-10-enhanced MR imaging. *Radiology.* 2009; 251:408–414. [PubMed: 19401573]

50. Koh D-M, Brown G, Temple L, Raja A, Toomey P, Bett N, Norman AR, Husband JE. Rectal cancer: mesorectal lymph nodes at MR imaging with USPIO versus histopathologic findings—initial observations. *Radiology*. 2004; 231:91–99. [PubMed: 14976266]
51. Sankineni S, Smedley J, Bernardo M, et al. Ferumoxytol as an intra-prostatic MR contrast agent for lymph node mapping of the prostate: a feasibility study in non-human primates. *Acta Radiol*. 2015;10.1177/0284185115586023
52. Lu M, Cohen MH, Rieves D, Pazdur R. FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease. *Am J Hematol*. 2010; 85(5):315–319. [PubMed: 20201089]




FIG. 1. Representative applications include detailed cardiovascular imaging (top) and assessment of tumor perfusion through pre-(bottom left) and postcontrast (bottom right) imaging in a patient with a single kidney nearly replaced by metastasis.

Table 1

Adverse Events and Administration Technique

A. Aggregate Adverse Events Reported in Postmarketing Safety Trials^a			
Event type	n (total n = 10425)	Total percent	Percent range
Gastrointestinal	174	1.74%	0.6–12.5%
Headache	57	4.21%	1.8–13.3%
Muscle spasm/arthralgias	40	2.96%	1.5–23.3%
Cough/sneezing	21	0.22%	0.1–5%
Pruritis/rash/flushing	68	0.68%	0.4–10%
Dizziness	56	0.56%	0.2–5%
Dyspnea/chest pain	48	0.48%	0.2–5%
Hypersensitivity	12	0.14%	0.1–0.1%
Hypotension	51	0.55%	0.4–2.5%
Peripheral edema	25	3.36%	2.5–3.5%
Anaphylaxis	3	0.03%	0.02–1.3%
CCAEE	9	0.89%	0.8–1%
Urinary tract infections, nasopharyngitis	39	5.67%	5.4–7.5%

B. Ferumoxytol Administration Technique at Rates Concordant with FDA Recommendations; Some Applications May Benefit from Bolus Infusion^a		
Parameter	Recommendation	Examples
Indications	Vascular imaging, oncology (perfusion, nodal metastasis)	Vascular mapping in renal insufficiency
Formulation	30 mg elemental iron/mL	
Full therapeutic dose	14.6 mg/kg (two 7.3-mg/kg doses over 3–8-day period)	For 70-kg adult, full dose is 1020 mg (two vials, one vial given at a time separated by a few days)
MRI dose	1–7.3 mg/kg	Venogram in 20-kg child using 3 mg/kg dose: 3 mg/kg * 20 kg = 60 mg (given 30 mg/mL formulation, 2-mL dose)
Dilution	1 part undiluted ferumoxytol in 2–4 parts normal saline (ie, to concentration of no higher than 10 mg/mL)	<i>Example 1:</i> 3 mg/kg dose in a 20-kg child: 60 mg = 2 mL ferumoxytol in 4-mL saline for a total of 6 mL <i>Example 2:</i> 3 mg/kg dose in a 100-kg patient: 3 mg/kg * 1 mL/30 mg * 100 kg = 10 mL ferumoxytol in 20-mL saline for a total of 30 mL
Infusion rate	Up to 0.5 mg/s	
Rapid bolus	Up to 2 mL/s (after dilution); NB: Not presently recommended by FDA	
Monitoring	Blood pressure, heart rate, and oxygen saturation before, 5 min after, and 30 min after administration	
Personnel	Physician with contrast reaction management training and ACLS and/or PALS certification in department; licensed nurse or physician in proximity to imaging suite	

^aHetzel et al (n = 406), Vadhan-Raj et al (n = 608), MacDougall et al (n = 80), Schiller et al (n = 8666), Auerbach et al (n = 60), Lu et al (n = 605) (52).

Note: Although bolus infusion has been reported in several imaging publications, the FDA labeling for ferumoxytol advises against bolus infusion.